sensit
specif
variou
sever
acut
respiratori
syndrom
coronaviru
sarscov
pcr
primer
probe
set
evalu
use
commerci
kit
inhous
amplif
format
convent
realtim
pcr
assay
perform
use
heatblock
thermocycl
abi
roch
lightcyclerk
version
abi
sequenc
detect
system
sensit
primer
pfu
viral
cell
lysat
pfu
spike
stool
specimen
per
pcr
assay
primer
set
realtim
pcr
assay
one
least
log
sensit
primer
set
use
convent
pcr
panel
virus
includ
swine
gastroenter
viru
bovin
coronaviru
avian
bronchiti
viru
connecticut
strain
avian
bronchiti
viru
massachusett
strain
human
coronavirus
parainfluenza
viru
type
iii
human
metapneumoviru
adenoviru
respiratori
syncyti
viru
influenza
test
assay
realtim
pcr
assay
use
probebas
detect
crossreact
observ
convent
pcr
analysi
perform
use
agaros
gel
electrophoresi
multipl
nonspecif
band
observ
two
commerci
extract
method
magnet
particl
captur
silicabas
procedur
evalu
result
compar
former
less
labori
shorter
time
complet
easili
adapt
autom
system
magna
purelc
extract
nucleic
acid
clinic
sampl
load
sampl
capillari
lightcyclerk
exemplifi
studi
continu
refin
evalu
pcr
procedur
greatli
benefit
diagnost
laboratori
outbreak
sar
sever
acut
respiratori
syndrom
sar
first
manifest
outbreak
sever
pneumonia
provinc
guangdong
china
novemb
ill
introduc
hong
kong
februari
spread
across
contin
period
week
intern
travel
approxim
peopl
worldwid
diagnos
probabl
sar
epidem
death
nation
advisori
committe
sar
public
health
canada
outbreak
sar
occur
mostli
mean
nosocomi
transmiss
acut
care
set
cultur
electron
microscopi
serolog
test
rtpcr
use
initi
investig
sar
outbreak
etiolog
agent
identifi
novel
coronaviru
sarscov
drosten
et
al
guan
et
al
ksiazek
et
al
lee
et
al
peiri
et
al
tsang
et
al
sever
communic
ill
rapid
sensit
diagnost
method
essenti
time
effect
institut
infect
control
measur
prevent
transmiss
studi
use
sever
set
primer
direct
polymeras
nucleocapsid
gene
sequenc
sarscov
inhous
assay
convent
realtim
amplif
compar
commerci
kit
artu
realartk
hpacoronaviru
lightcyclerk
rt
pcr
reagent
assay
artu
biotech
usa
inc
san
see
front
matter
elsevi
inc
right
reserv
francisco
roch
lightcyclerk
sarscov
quantif
kit
roch
diagnost
laval
term
specif
sensit
stool
specimen
submit
test
sar
outbreak
lee
et
al
peiri
et
al
yam
et
al
zhai
et
al
complex
heterogen
like
contain
differ
type
inhibitor
specimen
type
chosen
spike
experi
studi
sarscov
grown
vero
cell
level
iii
biohazard
contain
timani
et
al
complet
cytopath
effect
cpe
observ
infecti
materi
frozen
kept
stock
viru
use
titer
viru
determin
plaqu
assay
dilut
use
standard
protocol
briefli
viral
dilut
ad
vero
cell
monolay
prepar
cluster
plate
incub
hour
nutrientagar
overlay
ad
plate
place
co
incub
approxim
day
second
overlay
appli
contain
neutral
red
vital
stain
plate
check
plaqu
format
next
h
viral
cell
lysat
dilut
pb
ph
volum
ml
dilut
ad
ml
guanidinium
hydrochlorid
al
mixtur
use
rna
extract
twenti
randomli
select
stool
specimen
submit
viral
investig
pool
use
spike
experi
approxim
g
stool
weigh
wv
suspens
made
pb
ph
suspens
vortex
larg
particul
settl
al
stool
suspens
ad
al
viral
cell
lysat
dilut
mixtur
resuspend
pipet
aliquot
spike
dilut
remov
ad
al
guanidinium
hydrochlorid
suspens
vortex
aliquot
al
use
rna
extract
extract
rna
perform
dilut
viral
cell
lysat
spike
stool
sampl
commerci
kit
one
kit
use
silicabas
procedur
nuclisensr
stlaurent
quebec
use
magnet
bead
base
technolog
magazorbk
cortex
biochem
san
leandro
extract
rna
perform
per
manufactur
specif
rna
resuspend
al
depctreat
water
al
purifi
materi
use
rtpcr
method
compar
term
time
requir
complet
effici
rna
extract
primerprob
sequenc
amplicon
size
condit
rtpcr
instrument
use
amplif
detect
limit
summar
tabl
sequenc
primer
respect
locat
within
sarscov
genom
use
inhous
assay
shown
fig
qiagen
one
step
rtpcr
kit
qiagen
valencia
ca
use
standard
inhous
rtpcr
assay
primer
set
reaction
revers
transcript
follow
al
pcr
buffer
al
mmoll
dntp
al
primer
al
polymeras
mix
al
purifi
rna
revers
transcript
assay
perform
min
rt
follow
min
inactiv
pcr
paramet
describ
tabl
supercript
ii
rt
pcr
kit
invitrogen
life
technolog
burlington
use
primer
set
first
round
pcr
amplitaq
gold
roch
diagnost
use
nest
pcr
primer
set
superscript
ii
rta
invitrogen
life
technolog
use
revers
transcript
follow
pcr
amplitaq
gold
roch
diagnost
amplif
condit
carri
specifi
yam
et
al
amplif
al
amplifi
product
subject
wv
agaros
gel
electrophoresi
run
h
presenc
ethidium
bromid
agml
dna
size
marker
kbp
includ
gel
invitrogen
life
technolog
band
visual
uv
illumin
captur
use
polaroid
film
polaroid
cambridg
realtim
taqmanr
rtpcr
perform
primer
set
tabl
use
rtpcr
master
mix
kit
appli
biosystem
branchburg
nj
al
rna
sampl
primer
probe
use
concentr
nmoll
respect
inhous
realtim
lightcyclerk
rtpcr
assay
lightcyclerkrna
master
hybrid
probe
roch
diagnost
use
per
manufactur
instruct
along
set
primer
commerci
assay
artu
realartk
hpacoronaviru
lightcyclerk
rt
pcr
reagent
assay
roch
lightcyclerk
sarscov
quantif
kit
refer
artu
roch
assay
respect
throughout
studi
also
examin
artu
assay
readytous
kit
contain
reagent
enzym
amplifi
region
sarscov
genom
assay
multiplex
intern
control
identifi
presenc
inhibitor
sarscov
standard
also
provid
measur
viral
load
specimen
aliquot
al
extract
rna
ad
lightcyclerk
capillari
contain
al
pcr
reagent
amplif
paramet
list
tabl
roch
assay
amplifi
target
sequenc
replicas
abpolymeras
gene
sarscov
intern
control
use
set
primer
differ
intern
probe
also
includ
monitor
presenc
inhibitori
effect
standard
also
provid
quantifi
viral
load
test
sampl
requir
total
al
extract
rna
ad
al
pcr
reaction
mix
condit
amplif
list
tabl
artu
roch
assay
perform
roch
lightcyclerk
lc
version
panel
virus
includ
repres
major
coronavirida
group
speci
includ
test
specif
primer
set
swine
gastroenter
viru
bovin
coronaviru
avian
bronchiti
viru
connecticut
strain
avian
bronchiti
viru
massachusett
strain
human
coronavirus
well
parainfluenza
viru
type
iii
metapneumoviru
adenoviru
respiratori
syncyti
viru
influenza
rna
extract
viral
lysat
directli
use
silicaor
magnet
beadbas
technolog
extract
stool
spike
experi
viral
lysat
viral
panel
ad
stool
suspens
describ
section
titer
sarscov
stock
use
studi
pfuml
cpe
observ
round
earli
postinfect
dilut
viru
progress
rapidli
final
cell
detach
surfac
tube
aliquot
dilut
infecti
materi
use
determin
specif
sensit
viral
cell
lysat
stool
spike
experi
detect
limit
assay
summar
tabl
base
titer
obtain
plaqu
assay
input
viru
neat
per
al
extract
viral
cell
lysat
fecal
spike
sampl
pfu
use
endpoint
titrat
analysi
artu
roch
kit
demonstr
detect
limit
dilut
correspond
pfu
per
amplif
assay
fig
b
top
panel
spike
stool
sampl
end
point
dilut
pfu
per
assay
fig
b
b
top
panel
approxim
decreas
sensit
target
rna
extract
spike
stool
sampl
assay
intern
control
present
kit
ad
dilut
viral
cell
lysat
spike
stool
extract
amplif
monitor
presenc
inhibit
size
amplicon
gener
intern
control
primer
well
target
primer
inhibit
observ
extract
deriv
spike
stool
sampl
kit
also
provid
set
known
standard
incorpor
run
quantifi
number
rna
copi
requir
detect
level
demonstr
artu
roch
kit
copi
rna
per
reaction
respect
calcul
base
standard
provid
kit
bottom
panel
fig
b
gel
analys
amplifi
product
gener
realtim
rtpcr
commerci
assay
size
amplicon
artu
roch
kit
bp
respect
amplicon
gener
intern
control
primer
roch
kit
molecular
weight
target
amplicon
therefor
product
could
differenti
use
agaros
gel
electrophoresi
analysi
multipl
amplicon
band
produc
rtpcr
rna
templat
extract
spike
stool
sampl
fig
b
b
bottom
panel
viral
rna
specif
panel
fig
b
c
top
panel
howev
crossreact
observ
realtim
curv
analyz
fig
b
c
top
panel
specif
probe
use
assay
besid
commerci
kit
describ
set
primer
primer
set
design
realtim
amplif
use
roch
lightcyclerk
version
abi
sequenc
detect
system
sd
instrument
primer
set
target
nucleocapsid
gene
sequenc
wherea
primer
set
specif
polymeras
gene
viral
cell
lysat
pcr
endpoint
titrat
primer
set
primer
set
tabl
similar
drop
sensit
primer
observ
rna
extract
spike
stool
sampl
use
inhous
realtim
assay
posit
result
seen
nonsarscov
rna
specif
panel
howev
pcr
product
subject
agaros
gel
electrophoresi
analysi
multipl
band
present
b
fig
indic
hybrid
probe
differenti
product
nonspecif
amplicon
data
shown
intern
control
design
includ
reaction
presenc
inhibitor
caus
failur
amplif
would
detect
sensit
convent
block
pcr
assay
dilut
viral
cell
lysat
viral
cell
lysat
spike
stool
sampl
differ
set
primer
shown
fig
panel
b
detect
limit
agaros
gel
electrophoresi
analysi
primer
set
pfupcr
viral
cell
lysat
pfupcr
fecal
spike
sampl
endpoint
titrat
viral
cell
lysat
primer
set
respect
chang
sensit
pcr
endpoint
titrat
primer
set
fecal
spike
viral
cell
lysat
sampl
primer
set
drop
sensit
fecal
spike
sampl
pcr
endpoint
detect
also
weakli
stain
band
observ
slightli
lower
desir
amplicon
dilut
fig
band
excis
gel
dna
purifi
sequenc
compar
sarscov
coronaviru
sequenc
genbank
sequenc
data
show
resembl
coronaviru
genom
identif
presenc
viru
mainli
base
agaros
gel
electrophoresi
analysi
without
confirm
could
mistaken
weakposit
assum
low
viral
load
specimen
thu
falseposit
result
would
report
primer
set
except
amplifi
one
specif
product
nonspecif
product
even
presenc
fecal
materi
target
specif
fig
pcr
amplif
use
primer
set
result
mani
nonspecif
product
size
rang
bp
kbp
virus
specif
panel
band
also
similar
migrat
rate
amplicon
sarscov
primer
set
multipl
nonspecif
amplifi
product
also
produc
use
rna
extract
bovin
coronaviru
avian
bronchiti
viru
strain
c
swine
gastroenter
viru
parainfluenza
viru
crossreact
observ
primer
test
differ
virus
specif
panel
posit
result
obtain
sarscov
fig
panel
c
rna
also
test
use
primer
describ
crossreact
observ
data
shown
nucleic
acid
extract
one
factor
determin
effici
pcr
amplif
commerci
avail
extract
method
use
studi
one
method
use
silicabas
format
nuclisensr
magneticbas
extract
technolog
magazorbk
sensit
result
indic
endpoint
titrat
use
rna
extract
magazorbk
nuclisensr
compar
use
convent
realtim
pcr
total
time
extract
h
magazorbk
kit
compar
h
nuclisensr
kit
base
sampl
per
run
amount
handson
time
higher
latter
kit
although
case
sar
document
canada
past
year
futur
outbreak
still
possibl
frequenc
intern
travel
countri
affect
sar
report
attack
rate
greater
among
healthcar
worker
care
sar
patient
risk
infect
among
gener
popul
particularli
healthcar
worker
contact
suspect
sar
utmost
import
everi
laboratori
capabl
provid
sensit
accur
rapid
assay
earli
diagnosi
sar
implement
time
costeffect
infect
control
measur
investig
compar
differ
set
primer
target
variou
sequenc
sarscov
genom
inhous
assay
commerci
kit
commerci
kit
artu
roch
contain
intern
control
allow
monitor
extract
detect
inhibitori
factor
extrem
import
diagnost
laboratori
clinic
sampl
may
contain
inhibitor
might
interfer
pcr
result
amplif
failur
report
falseneg
result
pcr
inhibit
contributori
factor
falseneg
report
type
qualiti
specimen
time
collect
cours
diseas
play
critic
role
stool
chosen
spike
experi
heterogen
complex
like
contain
divers
inhibitori
factor
also
one
specimen
type
collect
sarscov
patient
diagnosi
although
inhibit
observ
fecal
sampl
spike
sarscov
mean
inhibit
problem
associ
clinic
sampl
elimin
use
silicaor
magneticbas
type
rna
extract
drosten
et
al
studi
inhibit
seen
one
pcr
assay
use
extract
rna
might
type
enzym
reagent
use
amplif
assay
wiedbrauk
et
al
avail
clinic
sampl
investig
artu
roch
kit
improv
detect
sarscov
sensit
stool
sampl
reach
drosten
et
al
versu
report
earlier
artu
assay
includ
set
intern
standard
concentr
copiesml
roch
assay
intern
standard
concentr
copiesml
use
extern
prepar
standard
recommend
hourfar
et
al
found
linear
measur
roch
assay
copi
extern
standard
rna
prepar
per
millilit
artu
assay
broader
linear
rang
copi
rnaml
hourfar
et
al
wide
dynam
rang
artu
assay
even
low
concentr
sarscov
measur
quantit
sensit
calcul
base
probabl
limit
n
copiesml
roch
assay
copiesml
artu
assay
hourfar
et
al
roch
assay
less
sensit
compar
artu
assay
might
amplicon
size
enzym
use
assay
amplifi
product
artu
assay
bp
compar
bp
roch
assay
combin
enzym
moloney
murin
leukemia
viru
revers
transcriptas
taq
dna
polymeras
use
artu
assay
wherea
roch
assay
appli
rtth
thermu
thermophilu
dna
polymeras
assay
combin
manganes
ion
rtpcr
enzym
rtth
less
suscept
gcrich
genom
inhibitor
howev
lack
sensit
low
concentr
viru
like
insuffici
revers
transcriptas
activ
cusi
et
al
contrari
observ
hourfar
et
al
studi
result
pcr
endpoint
titrat
kit
ident
detect
level
pfupcr
viral
cell
lysat
pfucpr
fecal
spike
sampl
design
inhous
primer
set
includ
studi
base
polymeras
nucleocapsid
gene
sensit
assay
compar
confirm
earlier
observ
drosten
et
al
indic
nucleocapsid
gene
abund
earli
stage
viral
infect
cell
cultur
therefor
pcr
assay
nucleocapsid
gene
target
would
like
increas
sensit
detect
symptomat
patient
convent
pcr
assay
perform
use
heat
block
format
abi
appli
biosystem
realtim
amplif
assay
conduct
roch
lc
version
abi
sd
instrument
primer
select
convent
pcr
realtim
pcr
ident
direct
comparison
sensit
could
made
type
assay
howev
primer
set
realtim
pcr
includ
studi
seem
one
least
log
sensit
primer
set
use
convent
pcr
accord
emeri
et
al
use
realtim
pcr
publish
primer
potenti
detect
limit
less
transcript
copi
per
pcr
greater
sensit
cell
cultur
isol
convent
pcr
lesser
effici
amplif
presenc
clinic
specimen
also
observ
data
also
show
drop
sensit
order
magnitud
addit
fecal
materi
sensit
amplif
assay
shown
improv
increas
volum
specimen
extract
realtim
pcr
coupl
modifi
extract
method
poon
et
al
poon
et
al
turnaround
time
convent
pcr
requir
minimum
h
cycl
time
longer
also
requir
gel
analysi
detect
multipl
nonspecif
band
variabl
size
observ
agaros
gel
electrophoresi
primer
set
use
primer
set
observ
nonspecif
pcr
band
rna
extract
spike
stool
sampl
might
occur
clinic
specimen
submit
diagnosi
insuffici
data
show
would
crossreact
submit
stool
sampl
clinic
sampl
without
probe
hybrid
restrict
digest
sequenc
amplicon
mean
confirm
potenti
report
falseposit
import
implic
especi
outbreak
set
sar
epidem
data
pcr
endpoint
titrat
show
rna
extract
magazorbk
kit
compar
result
obtain
rna
extract
nuclisensr
kit
kit
perform
equal
well
remov
inhibitor
shown
success
amplif
intern
control
pcr
assay
roch
artu
assay
kit
complet
handson
time
extract
less
fewer
consum
requir
magazorbk
kit
compar
nuclisensr
kit
basic
kit
cost
ident
choic
one
depend
expenditur
labor
consum
also
found
specimen
extract
magazorbk
kit
could
easili
adapt
magna
purelc
autom
nucleic
acid
extractor
roch
diagnost
instrument
also
dispens
extract
nucleic
acid
sampl
holder
capillari
roch
lc
version
extract
clinic
specimen
sar
move
autom
platform
minim
technic
requir
extrem
import
outbreak
situat
autom
rapid
turnaround
time
part
critic
factor
isol
treatment
patient
sar
great
impact
clinic
manag
therefor
import
use
differ
gene
target
nucleocapsid
gene
confirm
anoth
altern
refer
unopen
aliquot
specimen
anoth
laboratori
perform
sarscov
amplif
target
primer
equal
sensit
specif
posit
result
also
recommend
request
follow
specimen
amplif
also
serolog
cultur
although
much
emphasi
util
rtpcr
one
diagnost
tool
sar
sensit
result
obtain
interpret
caution
possibl
contamin
therefor
import
laboratori
personnel
conduct
test
meticul
techniqu
well
physic
separ
differ
step
manipul
clinic
specimen
studi
present
set
primer
use
realtim
rtpcr
convent
rtpcr
gelbas
detect
commerci
kit
detect
sarscov
artu
roch
assay
laboratori
realtim
instrument
perform
convent
pcr
intern
probe
specif
sarscov
amplicon
sequenc
amplicon
necess
avoid
falseposit
result
test
differ
clinic
specimen
requir
confirm
observ
perform
primer
set
respect
pcr
assay
howev
studi
provid
import
compar
data
sensit
specif
primer
current
use
differ
part
world
rapid
diagnosi
sarscov
